Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P

Benzinga

By Jeremy Golden, Benzinga A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear. As part of its randomized phase 2 AMPLIFY-7P study of ELI-002 7P as an adjuvant monotherapy in Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma (PDAC), Elicio Therapeutics Inc. (NYSE: ELTX) has dosed the first patient at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research in New York. ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by seven common mutations in KRAS: G12D, G12R, G12V, G12A, G12C, G12S and G13D. Those are present in 25% of all solid tumor cancers and 88% of PDAC patients. This is in contrast to other KRAS-targeted therapeutics in development, particularly small molecule KRAS inhibitors. Those target fewer mutations – potentially limiting the number of patients who can be treated – while also limiting the duration of benefit due to the development of escape mutants. The AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine. That data demonstrated tumor biomarker reduction, with strong T cell responses that correlated with reduced risk of relapse and death. Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development and Chief Medical Officer, anticipates results from this study will yield definitive data to support clinical efficacy assessment. Initial interim data on ELI-002 7P monotherapy from phase 1A arm will be shared in the first half of 2024, the company said. “Approximately 90% of pancreatic cancers are positive for KRAS mutations, with only rare G12C mutations, about 1%, amenable to small molecule treatment,” Haqq said. “ELI-002 represents a cancer vaccine approach that could potentially address the much broader spectrum of pancreatic cancer KRAS mutations.” In January, Elicio presented a Trial in Progress poster on the design of the AMPLIFY-7P trial at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The poster describes the phase 1 and randomized phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC). “ELI-002 is an off-the-shelf cancer vaccine candidate developed with our proprietary Amphiphile (“AMP”) platform which provides a new ability to deliver these treatments effectively to the ‘command center’ of the immune response – the lymph nodes – where tumor-fighting T cells are generated and equipped,” Haqq said. “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.” “Patients with RAS mutated pancreatic cancers who have positive circulating tumor DNA post-surgery are often quick to relapse,” added Zev A. Wainberg, M.D., Professor of Medicine, University of California, Los Angeles (UCLA), Co-Director, the UCLA GI Oncology Program. “Our current standard of care for these patients is observation — there are no treatments given during this ‘wait and see’ observation window before relapse. As we progress to Phase 2 of the study, we seek to compare ELI-002 7P to our current standard of care to further evaluate its antitumor activity and clinical benefit in the adjuvant setting as well as with bulkier cancer treated at the time of relapse in crossover patients with mKRAS-driven pancreatic cancer.” Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 01, 2024 08:15 AM Eastern Standard Time

University of Dayton Law School Leads the Way in Contract Excellence with the Adoption of the NCMA Contract Management Standard™

National Contract Management Association

The University of Dayton School of Law (UDSL) proudly announces its commitment to advancing education in Government Contracting & Procurement through the adoption of the National Contract Management Association's (NCMA) ANSI-approved Contract Management Standard™ (CMS™) and Contract Management Book of Knowledge ® (CMBOK ® ). The Master in the Study of Law (M.S.L.) in Government Contracting & Procurement program at UDSL is dedicated to providing students with the highest quality education and ensuring they are equipped with the knowledge and skills necessary for success in the ever-evolving profession of contract management. By incorporating the NCMA CMS™ and CMBOK ® into its program and course curricula, UDSL reaffirms its commitment to academic excellence and aligns with contract management best practices. Kraig Conrad, CEO of the National Contract Management Association, expressed enthusiasm about the partnership, stating, "We commend the University of Dayton School of Law for taking this progressive step for their program. This standard is a recognized benchmark in the profession, and its incorporation into UDSL's program reflects the university's dedication to providing students with a competitive edge in their careers." The NCMA CMS™ and CMBOK ® will serve as the foundation for UDSL's M.S.L. program, guiding the development of curriculum that addresses the dynamic and complex landscape of government contracting and procurement. This strategic adoption ensures that students receive comprehensive and up-to-date education and prepares them for success in the workforce. In response to the adoption, Sabra Tomb, UDSL’s Director of Training Programs and Strategic Business Development stated, "UDSL’s Government Contracting & Procurement Program is committed to delivering excellence in education and preparing our students to excel in their professional pursuits. The integration of the NCMA Contract Management Standard™ into our program is a testament to our dedication to providing a top-notch education that meets the needs of the industry and empowers our students for success." As UDSL continues to strengthen its position as a leader in legal education, this decision underscores its commitment to staying at the forefront of profession advancements and provide students with a competitive advantage in the job market. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. The School of Law offers a fully online master's program in government contracting and procurement designed by seasoned industry and government experts. The program is designed for contract professionals; a law degree is not required. Courses are taught in real-time to encourage active learning and provide opportunities for live feedback and interaction between faculty and students. Each class meets once a week, scheduled for working professionals. Financial aid, military, and veteran benefits; and corporate and government tuition deferment, assistance and reimbursement options are available. For more visit: https://udayton.edu/law/. Contact Details National Contract Management Association Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 01, 2024 05:00 AM Eastern Standard Time

News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in New Mexico

NuggMD

NuggMD, the nation's largest medical marijuana telemedicine platform, has launched its industry-leading service in New Mexico, the 28th state the company serves. Since its founding in 2015, NuggMD has connected over one million patients to medical marijuana physicians throughout the United States. New Mexico legalized cannabis for medical purposes in 2007 and for recreational use in 2021. In 2023, medical cannabis sales comprised nearly 26 percent of overall cannabis sales in the state, which totaled more than $50m. New Mexico taxes recreational cannabis at 12 percent, but that excise tax does not apply to the state’s medical sales. Since the inception of legal cannabis programs, sales in New Mexico have totaled more than $915m, according to state data, pulling hundreds of millions of dollars out of the state’s black market for the substance and funneling it into legal businesses that create jobs and contribute to the regional economy. “Where consumers get their cannabis matters a lot,” said Alex Milligan, NuggMD co-founder and CMO. “In California, for instance, our investigation confirmed that the state’s black-market cannabis is laced with pesticides and other contaminants, and the potencies don't match the labels. Purchasing from regulated retailers is the only way for consumers to be sure they’re using safe cannabis that’s honestly advertised.” It costs $99 to get a medical cannabis evaluation in New Mexico using NuggMD. The platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com/new-mexico. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

January 31, 2024 05:20 PM Eastern Standard Time

February is Pet Dental Health Month

YourUpdateTV

February is Pet Dental Health Month, which serves as a helpful reminder that there’s no better time to start prioritizing your cat or dog’s dental health. Recently, Dr. Danielle Bernal, the global veterinarian for Wellness® WHIMZEES®, participated in a nationwide satellite media tour to discuss Pet Dental Health Month and simple tips to help pet parents establish a dental routine. A video accompanying this announcement is available at: https://youtu.be/KhJpe-HTeGw 70% of cats will experience dental disease in their lifetime, and a vast 80% of dogs – especially small breeds and seniors – are at risk of dental disease. Lack of dental care can lead to inflammation, tartar, gingivitis, periodontal disease, and quality of life issues for your pet. Supporting dental health is vital to the overall wellbeing of both dogs and cats, and a steady dental health routine can significantly reduce the frequency and severity of issues in between visits to the vet. Incorporating a daily dental treat or chew option like Wellness® WHIMZEES® can go a long way toward ensuring pets will have healthier teeth, gums, and breath, and in turn, live happier lives. Wellness® WHIMZEES® allow pet parents to care for their pet’s dental health in an easy, enjoyable way and are crafted to support the 4 areas vets check most: Breath, Plaque, Tartar and Gums. Wellness® WHIMZEES® Brushzees® Natural Dental Treats for dogs are an ideal solution for daily dental care and have been awarded the Veterinary Oral Health Council (VOHC) approval seal. They arescientifically proven to lower plaque and tartar, supporting healthier teeth, gums, and fresher breath. Available in three delicious flavors, Chicken, Chicken & Salmon, and Chicken & Tuna, new Wellness® WHIMZEES® Natural Dental Treats for cats are designed with fresh chicken as the primary ingredient to offer a taste cats love. Wellness Pet’s latest innovation is set to support feline dental care and empower pet parents to treat them well while effortlessly contributing to their furry companions' oral wellbeing and ensuring a delightful experience. Options for both cats and dogs are conveniently available at pet specialty retailers, national retailers and online. To learn more about Wellness® WHIMZEES® and find them near you, visit https:// www.whimzees.com/. About Dr. Danielle Bernal Danielle Bernal, D.V.M., has over a decade of experience in veterinary medicine, specializing in animal nutrition. In her role as on-staff veterinarian at Wellness Pet Company, maker of premium natural food and treats for dogs and cats, including Wellness® WHIMZEES®, she educates pet parents and retailers alike on the importance of natural ingredients like wholesome meats and nutrient-rich superfoods and the highest quality standards. She passionately believes that proper nutrition helps pets lead happier, healthier lives and she shares that message with pet parents. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 31, 2024 10:48 AM Eastern Standard Time

Video

Cortland Biomedical Expands Cutting-Edge Capabilities and Capacity for Design and Development of Woven Biomedical Textile Structures

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, proudly announces the expansion of its weaving capabilities with the incorporation of two additional Jacquard Looms. This strategic move not only enhances the company's capacities, but also opens new avenues for groundbreaking advancements in medical textiles. Cortland Biomedical, in collaboration with global leaders in weaving equipment, integrates cutting-edge technologies into its machinery, ensuring excellence in every aspect from contact surfaces to yarn tensioning systems. Specializing in plain and narrow weave fabrics, including shuttle and rapier weaving, Cortland Biomedical excels in creating unique three-dimensional structures for applications like vascular grafts. These woven textiles, specifically designed for vascular and abdominal aortic aneurysm grafts and ensure limited blood flow. In addition, these woven textiles prove invaluable in orthopedics for bone and soft tissue repair, combining high strength with flexibility. Cortland Biomedical’s expertise positions it as a premier provider of tailored woven textile solutions for diverse medical applications. The addition of the two Jacquard Looms signifies a leap forward in Cortland Biomedical’s capabilities. This cutting-edge technology allows for unlimited possibilities in fabric design. Manipulating individual warp ends enables the creation of intricate structures, including bifurcations, convergences, tapers, and multi-layered fabrics. The fully electronic Jacquard loom offers unparalleled flexibility in altering fabric structures and patterns, significantly reducing material and time during prototyping. “Agility, curiosity, and credibility are at the heart of our mission, and set us apart as the easy-to-work-with partner our customers can count on to meet their unique medical device needs,” said Eric Brown, general manager, Cortland Biomedical. “Aligned with this strategy, our decision to add these Jacquard Looms was driven by our commitment to expanding capabilities, meeting the growing demands of the medical device industry, and fostering maximum innovation for our customers.” These looms boast the ability to weave thoracic size tubular grafts up to 46mm in diameter, create bifurcated structures as well as tapered flat and tubular structures, and generate infinite pattern designs through computer programming. With electronic let-offs designed for managing fine denier yarns, these looms can weave structures with high density and low permeability using polyesters, aramids, resorbables, and other fibers prominent in the medical device space. Cortland Biomedical will be exhibiting in booth 815 next week at MD&M West in Anaheim, CA. Eric and other company representatives will be on hand to discuss not only the company’s enhanced weaving abilities, but also its collaborative design and engineering processes, and capabilities for knitting, braiding and post-processing. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 31, 2024 10:00 AM Eastern Standard Time

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore™, the world’s first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). The additional indications are ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. PathExplore first launched in April 2023 with 8 indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. With this expansion, PathExplore human interpretable features (HIFs) will now be available across 14 oncology indications to accelerate the next phase of precision oncology. The last decade has seen significant strides in oncology drug development, but challenges remain – many cancer patients do not respond to available treatments, and many aren’t eligible for potentially transformative therapies because of a lack of actionable biomarkers. Distinct cell populations, tissue structures, and their spatial distributions across the TME represent some of the most promising areas of oncology research, however; traditional approaches are unable to access the full resolution of histopathology data at scale. “Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.” Since launch, PathExplore has established itself as the gold-standard in AI-powered digital pathology for oncology drug development. PathAI has partnered with over 50 pharma, biotech, academic, and laboratory partners to analyze >150,000 WSIs, resulting in 50+ publications and presentations. “PathExplore represents a tremendous leap forward in biological research, bypassing long standing constraints of many existing modalities by combining the widespread availability of H&E with the unprecedented resolution of AI,” said Mike Montalto, PhD, chief scientific officer at PathAI. “By expanding the availability of PathExplore’s structured pathology data into new disease areas, we’re empowering drug developers to continue to uncover insights that go beyond existing biomarkers.” To learn more about PathExplore, download our ebook that highlights real-world applications of AI-powered pathology solutions including PathExplore, in various stages of drug development programs. PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

January 30, 2024 10:00 AM Eastern Standard Time

American Medical Association Grants Cardio Diagnostics (NASDAQ: CDIO) Reimbursement Codes For AI-Powered Coronary Heart Disease Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics’ AI-driven coronary heart disease (CHD) tests have taken another promising step in their evolution. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, has been assigned two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA); 0440U for the company’s AI-driven CHD detection test, PrecisionCHD, and 0439U for the company’s AI-driven CHD event (heart attack) risk assessment test, Epi+Gen CHD. Assigned by the American Medical Association (AMA), these two new CPT PLA codes – effective April 1, 2024 – mark a significant step toward payer billing and payment for the company’s groundbreaking tests. The designation will facilitate the broader adoption of PrecisionCHD, an integrated genetic-epigenetic clinical blood test to aid in the diagnosis of CHD, and Epi+Gen CHD for evaluating the likelihood of a patient experiencing a CHD event – mainly a heart attack – within the next three years. Treating A Growing Problem Every year, about 805,000 people in the United States have a heart attack, meaning someone experiences a heart attack every 40 seconds. Heart disease is the leading cause of death for both men and women. According to the CDC, in 2021, heart disease was responsible for the deaths of more than 695,000 Americans – representing one in every five deaths. The most common type of heart disease and the major cause of heart attacks, CHD was responsible for over 375,000 deaths in 2021, and CHD-associated medical costs are estimated to be about $239.9 billion according to an estimate by the CDC in its heart disease fact sheet. Combating this growing problem, Cardio Diagnostics reports that PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. The PrecisionCHD test has the ability to aid in the diagnosis of CHD and provide personalized insights to help prevent a heart attack and improve outcomes. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Identifying patients with CHD and intervening before a heart attack occurs are essential to reducing the unprecedented economic and health burden associated with CHD. Until now, the lack of readily accessible and cost-effective diagnostic solutions for CHD has posed a challenge leading to delayed diagnosis and care, particularly among underserved and minority populations. Increasing access, the PrecisionCHD test only requires a simple blood draw and can be deployed remotely, allowing it to be scaled without the need for specialized infrastructure. This enables more timely intervention and management. “Receiving a dedicated CPT PLA code for PrecisionCHD is a critical milestone in our commercialization strategy,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “With PrecisionCHD, we believe that expanding equitable access to CHD diagnostics and improving patient health outcomes while reducing healthcare expenditure is possible.” While PrecisionCHD aids in diagnosing CHD, Cardio Diagnostics’ Epi+Gen CHD evaluates an individual’s genetic and epigenetics to predict their risk for a heart attack or sudden cardiac death associated with CHD. By leveraging the powerful personalized insights driven by the company’s groundbreaking epigenetic-genetic technology, the company can provide patient-specific epigenetic and genetic drivers of CHD to help guide preventive care that could potentially save lives. In peer-reviewed studies, Epi+Gen CHD was more cost-effective and sensitive for assessing heart attack risk when compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. For employers, the financial burden of heart attacks includes direct costs related to diagnosing, managing and treating heart disease. Indirect costs include lost productivity due to employee absenteeism and short-term disability, which can indirectly cost employers about $1,119 per month for upwards of three years. Cardio Diagnostics’ technology can help employers better inform their benefits offerings by combining the ability to offer employees the advanced Epi+Gen CHD heart attack risk test with aggregated risk data. Cardio Diagnostics’ Employer Risk Intelligence platform provides employers and brokers with the first-of-its-kind cardiovascular employee population health intelligence backed by a clinical test and layered insights, completed in a compliant manner. As such, Epi+Gen CHD’s new reimbursement code could mean greater access to technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. “Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers,” Dogan said. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks. The company is committed to making heart disease risk assessment, detection and management more accessible, and it believes personalized and precise diagnostics are key to winning the fight against the leading cause of death in the United States. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

January 30, 2024 08:20 AM Eastern Standard Time

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002

Benzinga

By Jeremy Golden, Benzinga Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and third leading causes of cancer death, respectively. Pancreatic and colorectal cancers are often Kirsten rat sarcoma (KRAS) mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. KRAS mutations are among the most prevalent human cancers. For these cancers, caused by a mutation of the KRAS gene, clinical-stage biotechnology company Elicio Therapeutics Inc. (NASDAQ: ELTX) is developing a pipeline of novel immunotherapies for treatment. Founded in 2011, Elicio Therapeutics has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s lead clinical program, ELI-002, is a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven cancers. It was designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors. ELI-002 2P has been studied in a phase 1 dose-escalation study in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy. After early findings from AMPLIFY-201 were released, ELI-002 was the subject of a publication in Nature Medicine. The paper — “ Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The phase 1 AMPLIFY-201 Trial ” — details expanded and updated results that point to the power of Elicio Therapeutics’ use of precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against solid tumors. Originally presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer, the data detailed in the publication is as of September 6, 2023. It is based on 25 patients with solid tumors (20 pancreatic, 5 colorectal) who were positive for minimal residual mKRAS disease after locoregional treatment. “When tumor DNA or protein persists or recurs after treatment, patients with pancreatic and colorectal cancers are unfortunately not left with many options and are often incurable,” said study author Shubham Pant, M.D., Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. “These are promising early findings from the AMPLIFY-201 study with follow up ongoing. Most patients reduced their tumor biomarkers with some having complete clearance following treatment with ELI-002.” “The lymph node-targeted cancer vaccine candidate induced direct ex vivo mKRAS-specific T cell responses in 84% of patients, with 59% of patients demonstrating a response with two key types of T cells: helper cells and killer cells,” according to Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer. “Past studies have not produced this large a fraction of patient response, this high a magnitude of a response or the expansion of both key populations of T cells,” he said. “Importantly, these T cell responses were specific to tumor-driver mutant KRAS neoantigens, correlated with reduced risk of relapse and we saw a pool of memory T cells form that we believe hold promise to confer long-term protection,” Haqq said. “We look forward to progressing ELI-002 into a randomized phase 2 trial as a monotherapy for patients with PDAC.” ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population for ELI-002 and possibly reducing the chance of bypass resistance mechanisms. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 30, 2024 08:10 AM Eastern Standard Time

InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need

Benzinga

By Meg Flippin, Benzinga Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all. The leader in cannabinoids and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization hit key milestones in advancing its cannabinoids-based treatments for Alzheimer’s disease, age-related macular degeneration (AMD) and epidermolysis bullosa in 2023 with more inroads to come in 2024. Take Alzehimer’s for starters. The disease is a big and growing problem afflicting about 6.7 million people 65 and older in the U.S. By 2060 it’s projected that 14 million people in the U.S. will suffer from the degenerative neurological disease. Treatments exist to address the symptoms related to memory and cognitive function and in some instances slow the rate of cognitive decline, but none have been able to reverse disease effects. Making An Impact InMed hopes to change that with INM-901, a rare cannabinoid analog the company says has the potential to target several biological pathways associated with Alzheimer’s. Previous industry research has shown cannabinoids hold promise in not only slowing the progress of Alzheimer’s but potentially reversing its effects thanks to their neuroprotective and regenerative properties. InMed’s data from preclinical i n vivo studies released last year showed INM-901 improved cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. To further evaluate INM-901 in 2024, InMed has initiated longer-term, six-month preclinical studies in behavior models. At the same time, the company is gearing up to launch more advanced preclinical studies, encompassing drug distribution, metabolism, active pharmaceutical ingredients and drug product formulation/manufacturing. Cannabinoids Can Protect Eyes Another big disease InMed is going after is age-related macular degeneration or AMD, which is a common cause of vision loss and potential blindness in people over 50. Based on 2019 estimates, AMD afflicts 19.8 million people or 12.6% of Americans 40 and up. Globally it affects 35% of people 74 and older. As it stands, there is no cure for AMD although treatment can prevent or slow the progression of the disease. Left unchecked patients may lose central field vision in the affected eye within 24 months of disease onset. INM-089, InMed’s ocular program for AMD launched in November is showing promise in changing that. Preclinical studies showed the potential for the drug to preserve retinal function, proactively protect the retinal cells that are responsible for vision and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated, InMed said. Coming off those positive results, InMed is engaged in advanced preclinical studies and drug product formulation work, and it plans to launch Investigational New Drug studies in mid-2024. The goal is to file an Investigational New Drug application with regulatory authorities in the first half of 2025. “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs,” said InMed CEO Eric A. Adams. “Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.” Dermatology Program Additionally, last year, the company successfully completed a phase 2 clinical trial in the treatment of epidermolysis bullosa or EB, a rare genetic skin disease marked by fragile skin that can lead to extensive blistering and wounding. Data from a phase 2 clinical trial of INM-755 showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone, warranting further development. InMed thinks INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments and is currently seeking partnerships for continued development. Supplier To All In addition to developing its own treatments, InMed is a key supplier of rare cannabinoids as ingredients to the health and wellness market. The company’s BayMedica unit focuses on being a low-cost/high-quality manufacturer of certain non-psychoactive rare cannabinoids and an ingredients supplier to brands within the health and wellness industry. In 2023, the company said the unit experienced “significant” year-over-year revenue growth, and it is making moves to capitalize on revenue-generating opportunities in 2024. To that end, BayMedica is embracing a distributor model to expand coverage across the U.S. InMed is betting consumer brands will use more rare cannabinoid ingredients in 2024 – and InMed will be ready to provide them. “BayMedica continues to drive robust year-over-year revenue growth. The foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoid ingredients continues to gain momentum,” said Adams. Cannabinoids hold promise to treat and potentially cure several diseases. InMed seems to be at the forefront of these groundbreaking advances. If 2023 is any indication, investors may want to watch for more milestones out of InMed this year and beyond. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 26, 2024 08:40 AM Eastern Standard Time

1 ... 29 30 31 32 33 ... 214